Jasper Therapeutics, Inc. (JSPR)
USD 21.01
(-6.41%)
USD 21.01
(-6.41%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -52.06 Million | -45.85 Million | -33.67 Million | -18.26 Million | -1.96 Million |
| Net Income | -64.46 Million | -37.68 Million | -30.63 Million | -31.66 Million | -4.98 Million |
| Depreciation & Amortization | 1.1 Million | 975 Thousand | 377 Thousand | 21 Thousand | - |
| Deferred income taxes | -4.38 Million | - | 3 Million | -21 Thousand | - |
| Stock-based compensation | 5.21 Million | 4.09 Million | 1.04 Million | 1.21 Million | 6000.00 |
| Change in working capital | 5.1 Million | -649 Thousand | 1.62 Million | 1.29 Million | 1.39 Million |
| Other non-cash items | 5.35 Million | -12.59 Million | -9.08 Million | 10.89 Million | 1.62 Million |
| Investing Cash Flow | -267 Thousand | -576 Thousand | -2.42 Million | 198.34 Thousand | - |
| Investments in PPE | -267 Thousand | -576 Thousand | -2.42 Million | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | 198.34 Thousand | - |
| Financing Cash Flow | 100.97 Million | 55 Thousand | 100.96 Million | 11.28 Million | 29.12 Million |
| Debt repayment | - | - | - | - | -1.5 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -960 Thousand | 28 Thousand | - | - | - |
| Common Stock Issuance | 101.93 Million | 55 Thousand | 10.75 Million | 11.28 Million | - |
| Other Financing Activities | -960 Thousand | 55 Thousand | 90.21 Million | 11.28 Thousand | 27.62 Million |
| Accounts receivables | 663 Thousand | -663 Thousand | 600 Thousand | - | - |
| Accounts payables | 2.38 Million | -2.15 Million | 2.93 Million | 358 Thousand | - |
| Inventory | - | 663 Thousand | -600 Thousand | - | - |
| Other working capital | 2.05 Million | 1.5 Million | -1.31 Million | 938 Thousand | 1.39 Million |
| Cash at beginning of period | 38.25 Million | 85.04 Million | 20.18 Million | 27.16 Million | 4.00 |
| Cash at end of period | 86.88 Million | 38.66 Million | 85.04 Million | 20.18 Million | 27.16 Million |
| Capital Expenditure | -267 Thousand | -576 Thousand | -2.42 Million | - | - |
| Effect of forex changes on cash | - | - | - | -198.34 Thousand | - |
| Net cash flow / Change in cash | 48.63 Million | -46.37 Million | 64.86 Million | -6.98 Million | 27.16 Million |
| Free Cash Flow | -52.33 Million | -46.43 Million | -36.1 Million | -18.26 Million | -1.96 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -14.58 Million | -13.72 Million | -16.58 Million | -64.46 Million | -17.54 Million | -16.08 Million |
| Depreciation & Amortization | 299 Thousand | 288 Thousand | 283 Thousand | 1.1 Million | 276 Thousand | 275 Thousand |
| Deferred income taxes | - | - | -831 Thousand | -4.38 Million | - | - |
| Stock-based compensation | 1.48 Million | 1.16 Million | 1.15 Million | 5.21 Million | 1.39 Million | 1.39 Million |
| Change in working capital | 1 Million | -3.6 Million | -1.42 Million | 5.1 Million | 4.12 Million | 1.46 Million |
| Other non-cash items | 1.74 Million | 3.63 Million | 915 Thousand | 5.35 Million | -228 Thousand | -318 Thousand |
| Investing Cash Flow | -157 Thousand | -25 Thousand | -230 Thousand | -267 Thousand | - | -11 Thousand |
| Investments in PPE | -157 Thousand | -25 Thousand | -230 Thousand | -267 Thousand | - | -11 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 181 Thousand | 47.34 Million | -271 Thousand | 100.97 Million | 36 Thousand | -305 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -299.00 | -960 Thousand | - | -661.00 |
| Common Stock Issuance | 181 Thousand | 47.34 Million | 28 Thousand | 101.93 Million | 36 Thousand | 356 Thousand |
| Other Financing Activities | 181.00 | 154 Thousand | -299 Thousand | -960 Thousand | 36.00 | -661 Thousand |
| Accounts receivables | - | - | -663 Thousand | 663 Thousand | - | - |
| Accounts payables | 457 Thousand | -1.75 Million | 893 Thousand | 2.38 Million | 1.67 Million | -2.26 Million |
| Inventory | - | - | -283 Thousand | - | - | - |
| Other working capital | 545 Thousand | -1.84 Million | -1.37 Million | 2.05 Million | 2.44 Million | 3.72 Million |
| Cash at beginning of period | 118.47 Million | 86.88 Million | 103.86 Million | 38.25 Million | 116.22 Million | 129.81 Million |
| Cash at end of period | 106.81 Million | 118.47 Million | 86.88 Million | 86.88 Million | 104.28 Million | 116.22 Million |
| Capital Expenditure | -157 Thousand | -25 Thousand | -230 Thousand | -267 Thousand | - | -11 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -11.65 Million | 31.58 Million | -16.98 Million | 48.63 Million | -11.94 Million | -13.58 Million |
| Free Cash Flow | -11.83 Million | -15.76 Million | -16.7 Million | -52.33 Million | -11.98 Million | -13.28 Million |
IDOX
7711
NLOP
PAYX
4HW
600765